Pralsetinib

3 trials

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

2 Completed trials

2 Sponsors

11 Countries

Phase III

Phase II

Phase III/IV

Phase III: 1 Phase II: 1 Phase III/IV: 1

Oversight events:

2 urgent safety measures across 2 trials

View oversight register →

Sponsors using this IMP

F. Hoffmann-La Roche AG 2 Rigel Pharmaceuticals Inc. 1

All trials

3 total

Pralsetinib (Gavreto) drug drug interaction study in patients with RET+ advanced or metastatic solid tumors. Pending

2025-523158-15-00 Phase III/IV 1 country Rigel Pharmaceuticals Inc.
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended

2023-507418-28-00 Phase II 8 countries F. Hoffmann-La Roche AG
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended

2023-505035-12-00 Phase III 10 countries F. Hoffmann-La Roche AG

Showing 1–3 of 3 trials

← All drugs A–Z